Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MEDIFAST INC (MED)

Medifast Q2 revenue falls 27.6% to $76.4 million; swings to $3.1 million net loss

Negative Impact 4 of 5 earnings Written later

Medifast reported second quarter 2026 revenue of $76.4 million, down 27.6% from $105.6 million a year earlier, and a net loss of $3.1 million, or $0.28 per diluted share, compared with net income of $2.5 million, or $0.22 per share, in the prior-year quarter. The company expects full year 2026 revenue of $270 million to $300 million and a loss of $0.25 to $1.75 per share, so shareholders face continued losses and lower sales.

Key points

  • Active earning coaches fell 48.7% to 11,700 from 22,800 a year earlier, and the company expects the number to keep declining in 2026.
  • Gross profit margin was 69.9%, down from 72.6%, and loss from operations was $4.3 million versus $1.1 million a year earlier.
  • Full year 2026 guidance: revenue of $270 million to $300 million and loss per share of $0.25 to $1.75.
  • Third quarter 2026 guidance: revenue of $60 million to $80 million and loss per share of $0.15 to $0.65, excluding one-time Catalyst program costs.

The filing

CompanyMEDIFAST INC (MED)
Form8-K, current report
Filed with the SECAug 3, 2026, 4:12 PM ET
Accession number0001628280-26-051845

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.